References
- Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death. World J Cardiol. 2010; 2:289–98.
- Li J, Umar S, Amjedi M, Iorga A, Sharma S, Nadadur RD, et al. New frontiers in heart hypertrophy during pregnancy. Am J Cardiovasc Dis. 2012; 2:192–207.
- O’Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, Toldo S. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med. 2014; 20:221–9.
- Wang M, Markel TA, Meldrum DR. Interleukin 18 in the heart. Shock. 2008; 30:3–10.
- Hartford M, Wiklund O, Hultén LM, Persson A, Karlsson T, Herlitz J, et al. Interleukin-18 as a predictor of future events in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2010; 30:2039–46.
- Badimon L. Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis. Cardiovasc Res. 2012; 96:172–5.
- Colston JT, Boylston WH, Feldman MD, Jenkinson CP, de la Rosa SD, Barton A, et al. Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochem Biophys Res Commun. 2007; 354:552–8.
- Nebigil CG, Choi D-S, Dierich A, Hickel P, Le Meur M, Messaddeq N, et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A. 2000; 97:9508–13.
- Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, et al. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int. 2015; 2015:438403. doi: 10.1155/2015/438403
- Nebigil CG, Jaffré F, Messaddeq N, Hickel P, Monassier L, Launay JM, Maroteaux L. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation. 2003; 107:3223–9.
- Liang Y-J, Lai L-P, Wang B-W, Juang S-J, Chang C-M, Leu J-G, Shyu K-G. Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-κB in cardiomyocytes. Cardiovasc Res. 2006; 72:303–12.
- Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res. 2009; 104:113–23.
- Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal. 2009; 11:1415–52.
- Zheng Y, Song HJ, Kim CH, Kim HS, Kim E-G, Sachinidis A, Ahn HY. Inhibitory effect of epigallocatechin 3-O-gallate on vascular smooth muscle cell hypertrophy induced by angiotensin II. J Cardiovasc Pharmacol. 2004; 43:200–8.
- Won S-M, Park Y-H, Kim H-J, Park K-M, Lee W-J. Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med. 2006; 38:525–34.
- Villeneuve C, Caudrillier A, Ordener C, Pizzinat N, Parini A, Mialet-Perez J. Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009; 297:H821–8.
- Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp Cell Res. 1976; 98:367–81.
- Ayme-Dietrich E, Aubertin-Kirch G, Maroteaux L, Monassier L. Cardiovascular remodeling and the peripheral serotonergic system. Arch Cardiovasc Dis. 2017; 110:51–9.
- Cheng K-C, Chang W-T, Li Y, Cheng Y-Z, Cheng J-T, Chen Z-C. GW0742 activates peroxisome proliferator-activated receptor δ to reduce free radicals and alleviate cardiac hypertrophy induced by hyperglycemia in cultured H9c2 cells. J Cell Biochem. 2018; 119:9532–42.
- Chandrasekar B, Mummidi S, Claycomb WC, Mestril R, Nemer M. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem. 2005; 280:4553–67.
- Chandrasekar B, Boylston WH, Venkatachalam K, Webster NJ, Prabhu SD, Valente AJ. Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-κB/PTEN suppression. J Biol Chem. 2008; 283:24889–98.
- Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, et al. Requirement of nuclear factor-κB in angiotensin II– and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005; 111:2319–25.
- Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides. 2019; 111:18–25. doi: 10.1016/j.peptides.2018.05.012
- Murray DR, Mummidi S, Valente AJ, Yoshida T, Somanna NK, Delafontaine P, et al. β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo. J Mol Cell Cardiol. 2012; 52:206–18.
- Lagha AB, Grenier D. Tea polyphenols inhibit the activation of NF-κB and the secretion of cytokines and matrix metalloproteinases by macrophages stimulated with Fusobacterium nucleatum. Sci Rep. 2016; 6:34520. doi: 10.1038/srep34520
- Hao J, Kim C-H, Ha T-S, Ahn H-Y. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci. 2007; 8:121–9.
- Planavila A, Laguna JC, Vázquez-Carrera M. Nuclear factor-κB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem. 2005; 280:17464–71.
- Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M. Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005; 65:832–41.
- Nebigil CG, Maroteaux L. Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation. 2003; 108:902–8.
- Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013; 4:289. doi: 10.3389/fimmu.2013.00289